AVEO Pharmaceuticals — Investor Presentation (April 2015)
38 slides from AVEO Pharmaceuticals's investor presentation, Apr 8, 2015
Slide 1: Corp Overview April 2015
1 Exhibit 99.1 April 2015 CORP OVERVIEW
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate
Slide 3: Leveraging Biomarkers and Partnerships to Advance Robust Pipeline
AVEO is Leveraging Biomarkers and Partnerships in Seeking to Advance its Robust Pipeline of Assets Substantial Ownership of all Programs Most advanced stage of development Program Development Pathway Candidate Preclinical Phase 1 Phase 2 Phase 3 Rights Tivozanib Own ex-Asian VEGFR 123 TKI Potential
Slide 4: Tivozanib
Tivozanib A POTENT, SELECTIVE, LONG HALF-LIFE INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 1, 2, AND 3 RECEPTORS
Slide 5: Tivozanib – VEGFR 1, 2 & 3 Tyrosine Kinase Inhibitor
Tivozanib – VEGFR 1, 2 & 3 Tyrosine Kinase Inhibitor • Potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 • Patent term: 2022 (composition of matter) with potential extension to 2027 • Orphan drug de
Slide 6: Tivozanib Preclinical Activity in Ocular Models
Tivozanib Preclinical Activity in Ocular Models Compared to the vehicle-treatment, tivozanib suppressedthe development ofCNVlesionsand led to a significantregression ofestablished CNV, reducing the affected areas by 80.7% and 67.7% respectively April 8, 2015 6 6
Slide 7: Ophthotech Research and Option Agreement: Nov. 2014
Ophthotech Research and Option Agreement: Nov. 2014 Agreement monetizes tivozanib while retaining oncology indications and providing significant potential downstream value for AVEO Agreement Research and Exclusive Option Agreement for Non-Oncology Disease of the Eye Territory Worldwide ex-Asia Upfro
Slide 8: Current Anti-VEGF Market: Expanding Multi-Billion Dollar Opportunity
Current Anti-VEGF Market: Expanding Multi-Billion Dollar Opportunity Annual Global Branded Anti-VEGF Sales* ($8n) 6.4 6.0 $0 48 40 ane 3.0 2 2.3 20 18 1.2 oo | 2006 2007 2008 2009 2010 2011 2012 2013 “Cphinctech Mane! exirete Sales in First 12 Months Following Launch Lucentis sais SSO0MM *Eylea $862
Slide 9: Evaluating Potential for MAA Filing for RCC
Evaluating Potential for MAA Filing for RCC TIVO-1 Randomized Phase 3 • Met primary PFS endpoint of superiority vs sorafenib • First H2H RCC pivotal trial to show superiority over another VEGF TKI • Demonstrated differentiated safety profile • OS confounded by crossover • Median OS similar to histor
Slide 10: Favorable OS Trend Including All US and EU Patients in TIVO-1
Favorable OS Trend when Including All US and EU Patients Enrolled in TIVO-1 (186 patients) NA/EU Overall Survival TIVO-1 (N=186) HR=0.89 Unstratified Analysis p=0.58 HR=0.87 Primary Stratified Analysis p=0.49 Includes: US, Canada, EU Member States (Bulgaria, Czech Republic, France, UK, Hungary, Ital
Slide 11: Efficacy Data for All US and EU Patients Enrolled in TIVO-1
Efficacy Data for All US and EU Patients Enrolled in TIVO-1 (186 patients) Progression Free Survival (PFS) Overall Survival (OS) Tivozanib Sorafenib Tivozanib Sorafenib N = 98 N = 88 N = 98 N = 88 14.7 8.5 35.9 31.0 Median PFS Median OS (21.9, NA) (24.1, 42.1) (9.2, 18.0) (5.7, 10.9) PFS Unstratifie
Slide 12: TIVO-1 Post-VEGF TKI Progression Data Compare Favorably to Competing Agents
Data from the TIVO-1 Study for Treatment Post-VEGF TKI Progression Compare Favorably to Competing Agents TIVO-1: AXIS: Dovitinib study: nd nd rd Phase3, 2 lineRCC Phase3, 2 lineRCC Phase3, 3 lineRCC Study subset crossing over to axitinib vs sorafenib dovitinib vs sorafenib tivozanib following (1:1)
Slide 13: Potential Phase 3 Confirmatory Study Design in Recurrent/Metastatic RCC
Potential Phase 3 Confirmatory Study Design in Recurrent/Metastatic RCC Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma N = 300 -400 • 1O: PFS tivozanib • 2O: OS, ORR, DoR, • Recurrent/metasta
Slide 14: Colorectal Cancer (CRC)
Colorectal Cancer (CRC) N = 265 tivozanib • 1O: PFS* st + • 2O: OS, ORR, DoR, • 1 line Stage IV mCRC mFOLFOX6 TTF, HRQol, Safety • No fluorouracil adj tx <6 months and tolerability for • ECOG PS 0 or 1 bevacizumab ITT & Pre-Specified + Biomarkers mFOLFOX6 • Final results (AACR Angiogenesis 2015) sug
Slide 15: Tivozanib Comparable PFS Outcomes as Avastin in ITT Population
Tivozanib Treatment Resulted in Comparable PFS Outcomes as Avastin in ITT Population; Investigator Assessment April 7, 2015 15 CI, confidence interval; HR, hazard ratio
Slide 16: NRP-1 Levels Prognostic for PFS for Tivozanib and Bevacizumab
NRP-1 Levels Were Prognostic for PFS for both Tivozanib (A) and Bevacizumab (B) Treated Patients* (A) PFS for tivozanib arma (B) PFS for bevacizumab armb NRP-1 low (n=52) NRP-1 low (n=28) Median PFS=17.9 months Median PFS=11.2 months NRP-1 high (n=26) NRP-1 high (n=56) Median PFS=7.5months Median PF
Slide 17: NRP-1 Low Predictive for Tivozanib Benefit over Bevacizumab
NRP-1 Low (A) Was Predictive for Tivozanib Benefit over Bevacizumab while High (B) Levels Were Not* (A) NRP-1 lowa,b (B) NRP-1 high c,d Tivozanib (n=52) Median PFS=17.9 months Tivozanib (n=56) Median PFS=7.33 months Bevacizumab (n=26) Bevacizumab (n=28) Median PFS=7.46 months Median PFS=11.2 months
Slide 18: Similar Prognostic Value of NRP-1 in Renal and Other Cancers
Similar Prognostic Value of NRP-1 Observed in Renal and Other Cancers for VEGF inhibitors TIVO-1: Tivozanib-Treated Patients With High vs Low NRP-1 Levels Based on a Median Cutoff • Similar observations across several tumor types, including breast, gastric and colorectal cancers, with anti-VEGF ther
Slide 19: Where Are We Now with Tivozanib?
Where Are We Now with Tivozanib? • RCC EU – Rapporteur meetings scheduled to discuss opportunity for EU file with st TIVO-1 data for 1 line RCC (2Q15) • RCC Global – Planned ASCO 2015 presentation of updated VEGF TKI refractory PFS data from TIVO-1 crossover – FDA meeting scheduled to discuss potent
Slide 20: Ficlatuzumab
Ficlatuzumab A POTENT HEPATOCYTE GROWTH FACTOR (HGF) INHIBITORY ANTIBODY THAT BINDS TO THE HGF LIGAND WITH HIGH AFFINITY AND SPECIFICITY TO INHIBIT THE BIOLOGICAL ACTIVITIES OF HGF/c-MET PATHWAY 20
Slide 21: Ficlatuzumab – Humanized IgG1k MAb Inhibitor of HGF
Ficlatuzumab – Humanized IgG1k MAb Inhibitor of HGF • A Favorable Profile to In-Class Antibodies – High affinity (pM) and slow off-rate for HGF – High potency (nM) inhibiting all biological activities of HGF, including autocrine/paracrine activation loops – In vivo preclinical efficacy superior to i
Slide 22: Ficlatuzumab Randomized Phase 2 Study: Exploratory Analysis Results
Ficlatuzumab Randomized Phase 2 Study (P06162): Exploratory Analysis Results* VeriStrat ® may be a predictive biomarker for the combination of ficlatuzumab + EGFR TKI over EGFR TKI alone VeriStratPoor(VSP) ficlatuzumab + gefitinib gefitinib alone n=18 n=17 Median 23.9 months 5.8 months OS HazardRati
Slide 23: Biodesix Partnership: April 2014
Biodesix Partnership: April 2014 AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic – Unique collaboration where the diagnostic company provides funding for POC clinical development in NSCLC • Biodesix will fund up to $15 million of the cost of the con
Slide 24: FOCAL Study – Confirmatory Phase 2
FOCAL Study – Confirmatory Phase 2 A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label ficlatuzumab N = 86 +
Slide 25: AV-203
AV-203 A POTENT ERBB3 (HER3) INHIBITORY ANTIBODY DESIGNED TO INHIBIT BOTH LIGAND- DEPENDENT AND LIGAND-INDEPENDENT ERBB3 SIGNALING 25
Slide 26: AV-203: Superhumanized IgG1k MAb Inhibitor of ERBB3
TM AV-203: Superhumanized IgG1k MAb Inhibitor of ERBB3 • Potent high affinity NRG-1/HRG binding inhibition – Exclusively blocks ERBB3 signaling – Potential for inducing ADCC – Prevents NRG-1/HRG induced proliferation – Opportunity to explore combinations with HER2 and EGFR Targeted Therapies • Paten
Slide 27: Phase 1 AV-203 Dose-Escalation, Monotherapy Study Completed
Phase 1 AV-203 Dose-Escalation, Monotherapy Study Completed* NSCLC with partial response (9 mg/kg) • 22 subjects enrolled (NRG-1/HRG Positive) – Tumor types: 4 NSCLC (3 sq, 1 adeno); 4 CRC; 2 sq cell skin; one each ovarian, peritoneal, SCLC, endometrioid, osteosarcoma, HCC, pancreatic, neuroendocrin
Slide 28: AV-203 Combination Therapy Could Prevent Resistance
Combination Therapy: AV-203 combined with both afatinib or cetuximab could be effective in preventing resistance Treatment of FaDu Xenograft with AV-203 Prevents Resistance to Other EGFR and EGFR/HER2 Inhibitors 2000.0 PBS 1800.0 Xolair 20mpk AV- 203 20mpk 1600.0 Erbitux 5mpk 1400.0 Afatinib 12.5mpk
Slide 29: AV-380
AV-380 POTENTIAL FIRST-IN-CLASS GDF15 INHIBITORY ANTIBODY 29
Slide 30: Cachexia Represents a Significant Unmet Medical Need
Cachexia Represents a Significant Unmet Medical Need Cachexia: Complex metabolic syndrome associated with several underlying chronic illnesses and characterized by loss of muscle mass and strength, loss of whole body fat, inflammation, anemia, etc. Cachexia (Wasting Syndrome) Congestive Chronic Chro
Slide 31: GDF15 – Driver of Cachexia Proof-of-Concept
GDF15 – Driver of Cachexia (Wasting Syndrome) GDF15 Levels – Murine Models Proof-of-Concept: Elevated in cachectic models and patients (vs. non-cachectic) • Administration of GDF15 induces cachexia GDF15 Levels – Patient Samples • Inhibition of GDF15 reverses cachexia 31
Slide 32: GDF15 – Driver of Cachexia Proof-of-Concept
GDF15 – Driver of Cachexia (Wasting Syndrome) Proof-of-Concept: Elevated in cachectic models and patients (vs. non-cachectic) Administration of GDF15 induces cachexia Inhibition of GDF15 reverses cachexia 32
Slide 33: GDF15 – Overall Survival in Xenograft Model
GDF15 – Driver of Cachexia (Wasting Syndrome) Proof-of-Concept: Overall Survival in Xenograft Model Elevated in cachectic Anti-mGDF15 Ab + Drug A models and patients IgG Vehicle + Drug A (vs. non-cachectic) IgG Vehicle Administration of GDF15 induces cachexia Inhibition of GDF15 reverses cachexia In
Slide 34: First-in-Class, Differentiated Approach to Cachexia
First-in-Class, Differentiated Approach to Cachexia • AV-380: Potent humanized GDF15 inhibitory MAb – Unique mechanism of action • Increase calorie/food intake • Reverse body weight loss • Restore normal body composition • Mechanism of action different from: – Hormonal/Metabolic agents (i.e. ghrelin
Slide 35: Financials and Summary
Financials and Summary April 7, 2015 35
Slide 36: Financials Highlights
Financials Highlights • Streamlined operations • Headcount reduction from 60 to 20. Expected to reduce annual compensation expenses by ~$6 million • Reduce AVEO’s facilities requirements by up to 80% of its current space, including the elimination of lab and vivarium needs • Provided termination not
Slide 37: AVEO Poised to Unlock Potential of its Robust Pipeline
AVEO is Poised to Unlock the Potential of its Robust Pipeline of Assets by Leveraging Biomarkers and Partnerships Substantial Ownership of all Programs Most advanced stage of development Program Development Preclinical Phase 1 Phase 2 Phase 3 Rights Pathway Candidate Tivozanib Potential EU File 1st
Slide 38: April 2015 Corp Overview
4FNEO ONCOLOGY April 2015 CORP OVERVIEW
AVEO Pharmaceuticals — Investor Presentation (April 2015) on 6ix